Literature DB >> 8287957

Effect of pulmonary hypertension on gas exchange.

A G Agustí1, R Rodriguez-Roisin.   

Abstract

This paper reviews the effects of pulmonary artery hypertension on gas exchange by exploring three different issues, namely: 1) how does gas exchange behave in diseases characterized by increased vascular tone (primary pulmonary hypertension (PPH), chronic obstructive pulmonary disease (COPD) and interstitial pulmonary fibrosis (IPF)) or decreased vascular tone ("hepatopulmonary syndrome"); 2) how does exercise, as a non-pharmacological tool of increasing pulmonary blood flow, modify gas exchange in these diseases; and 3) how do several drugs that lower (vasodilators) or increase (almitrine) the active component of pulmonary hypertension interact with gas exchange. Available data show that: 1) in PPH a high pulmonary vascular tone enhances gas exchange and when it is lowered, either by oxygen or vasodilators, ventilation perfusion (VA/Q) distributions deteriorate; 2) in COPD a lowered (vasodilators) or augmented (almitrine) active vascular tone is almost invariably paralleled by a deterioration or enhancement of ventilation-perfusion matching, respectively; 3) in IPF an adequate active response of the pulmonary vasculature is essential to maintain gas exchange, both at rest and during exercise; and 4) in patients with liver cirrhosis a low pulmonary vascular tone induces an abnormal VA/Q distribution. In summary, these data show that any situation and/or therapeutic intervention that lowers the active vascular tone deteriorates VA/Q relationships and vice versa. The final effect of pulmonary vascular tone on arterial oxygen tension (PaO2) is less predictable. The reason for this uncertainty is that the actual PaO2 value depends on the interplay of the intra- and extrapulmonary factors that control gas exchange in humans, and not only on the degree of VA/Q mismatching.

Entities:  

Mesh:

Year:  1993        PMID: 8287957

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.

Authors:  Athanasios Charalampopoulos; J Simon R Gibbs; Rachel J Davies; Wendy Gin-Sing; Kevin Murphy; Karen K Sheares; Joanna Pepke-Zaba; David P Jenkins; Luke S Howard
Journal:  J Appl Physiol (1985)       Date:  2016-07-14

2.  Pulmonary hemodynamics responses to hypoxia and/or CO2 inhalation during moderate exercise in humans.

Authors:  Stéphane Doutreleau; Irina Enache; Cristina Pistea; Bernard Geny; Anne Charloux
Journal:  Pflugers Arch       Date:  2018-03-03       Impact factor: 3.657

Review 3.  New perspectives on management of idiopathic pulmonary fibrosis.

Authors:  Silvia Puglisi; Sebastiano Emanuele Torrisi; Virginia Vindigni; Riccardo Giuliano; Stefano Palmucci; Massimiliano Mulè; Carlo Vancheri
Journal:  Ther Adv Chronic Dis       Date:  2016-02-01       Impact factor: 5.091

4.  Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD.

Authors:  Karin Vonbank; Georg Christian Funk; Beatrice Marzluf; Bernhard Burian; Rolf Ziesche; Leopold Stiebellehner; Ventzislav Petkov; Paul Haber
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Hypoxia following etorphine administration in goats (Capra hircus) results more from pulmonary hypertension than from hypoventilation.

Authors:  Leith Carl Rodney Meyer; Robyn Sheila Hetem; Duncan Mitchell; Andrea Fuller
Journal:  BMC Vet Res       Date:  2015-02-03       Impact factor: 2.741

Review 6.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

Review 7.  Modulating cGMP to treat lung diseases.

Authors:  Hossein-Ardeschir Ghofrani; Friedrich Grimminger
Journal:  Handb Exp Pharmacol       Date:  2009
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.